{"id":3287,"date":"2025-10-06T05:52:40","date_gmt":"2025-10-06T05:52:40","guid":{"rendered":"https:\/\/genoks.com.tr\/docs\/genoxhere-brca-az\/"},"modified":"2026-05-01T21:43:16","modified_gmt":"2026-05-01T21:43:16","password":"","slug":"genoxhere-brca-az","status":"publish","type":"docs","link":"https:\/\/genoks.com.tr\/az\/docs\/genoxhere-brca-az\/","title":{"rendered":"BRCA Geni n\u0259dir? GenoXhere BRCA n\u0259l\u0259ri \u0259hat\u0259 edir?"},"content":{"rendered":"

<\/p>\n

BRCA Geni n\u0259dir? GenoXhere BRCA n\u0259l\u0259ri \u0259hat\u0259 edir?<\/strong><\/p>\n

BRCA1 v\u0259 BRCA2 homolog rekombinasiya yolu il\u0259 DNT c\u00fct-z\u0259ncir qopu\u011funun t\u0259miri \u00fc\u00e7\u00fcn vacib \u015fi\u015f supressor genl\u0259rdir. H\u0259r hans\u0131 birind\u0259 patojenik germ-line variantlar h\u0259yat boyu d\u00f6\u015f (~55-72% BRCA1, ~45-69% BRCA2), yumurtal\u0131q (~39-44% BRCA1, ~11-17% BRCA2), prostat, pankreas v\u0259 ki\u015fi d\u00f6\u015f x\u0259r\u00e7\u0259ngl\u0259ri riskini \u0259h\u0259miyy\u0259tli d\u0259r\u0259c\u0259d\u0259 art\u0131r\u0131r. GenoXhere BRCA paneli h\u0259r iki geni b\u00f6y\u00fck yenid\u0259nqurmalar (MLPA) daxil olmaqla sekvenslama edir v\u0259 ACMG\/AMP 2015 meyarlar\u0131na g\u00f6r\u0259 variantlar\u0131 bildirir.<\/p>\n

Kim test olunmal\u0131d\u0131r:<\/strong> NCCN qaydalar\u0131na g\u00f6r\u0259 \u015f\u0259xsi\/ail\u0259vi erk\u0259n ba\u015flan\u011f\u0131cl\u0131 d\u00f6\u015f x\u0259r\u00e7\u0259ngi (\u226450 ya\u015f), ist\u0259nil\u0259n ya\u015fda yumurtal\u0131q x\u0259r\u00e7\u0259ngi, ki\u015fi d\u00f6\u015f x\u0259r\u00e7\u0259ngi, \u226460 ya\u015fda triple-negative d\u00f6\u015f x\u0259r\u00e7\u0259ngi, A\u015fkenazi Y\u0259hudi m\u0259n\u015f\u0259yi v\u0259 metastatik prostat v\u0259 ya pankreas x\u0259r\u00e7\u0259ngi tarixi. Da\u015f\u0131y\u0131c\u0131lar \u00fc\u00e7\u00fcn klinik idar\u0259etm\u0259 25 ya\u015fdan illik d\u00f6\u015f MR-i, 30 ya\u015fdan mammoqrafiya, 35-40 (BRCA1) v\u0259 ya 40-45 (BRCA2) ya\u015fda risk-azald\u0131c\u0131 salpingo-ooforektomiya v\u0259 se\u00e7ilmi\u015f x\u0259r\u00e7\u0259ngl\u0259rd\u0259 PARP inhibitor terapiyas\u0131n\u0131 \u0259hat\u0259 edir.<\/p>\n

<\/p>\n

BRCA Geni Nedir?<\/strong><\/p>\n

BRCA, meme kanseri ve yumurtal\u0131k kanseri gibi kanser t\u00fcrlerine yatk\u0131nl\u0131k olu\u015fturan genlerin ad\u0131d\u0131r. BRCA1 ve BRCA2 olarak bilinen iki farkl\u0131 gen, normalde kanserin \u00f6nlenmesine yard\u0131mc\u0131 olan DNA tamirinde g\u00f6revlidir.<\/p>\n

\"GenoXhere

GenoXhere BRCA<\/p><\/div>\n

Ancak, baz\u0131 insanlarda bu genlerde do\u011fal bir mutasyon meydana gelir ve bu ki\u015filer meme kanseri, yumurtal\u0131k kanseri ve di\u011fer kanser t\u00fcrlerine yakalanma riski ta\u015f\u0131rlar. Bu ki\u015filer, BRCA mutasyonlar\u0131ndan kaynaklanan kanser riskini azaltmak i\u00e7in \u00e7e\u015fitli \u00f6nleyici tedbirler alabilirler. BRCA mutasyonlar\u0131n\u0131n ke\u015ffi, ailelerde genetik ge\u00e7i\u015fli meme kanseri ve yumurtal\u0131k kanseri riskini belirlemeye yard\u0131mc\u0131 olabilir ve risk alt\u0131ndaki bireylerin erken te\u015fhis ve \u00f6nleyici tedbirler almas\u0131n\u0131 sa\u011flayabilir.<\/p>\n\n\n\n\n\n\n\n\n
Gen :<\/strong><\/td>\nBRCA1 | BRCA2<\/td>\n<\/tr>\n
Y\u00f6ntem :<\/strong><\/td>\nT\u00fcm Gen Dizi Analizi<\/td>\n<\/tr>\n
Raporlama S\u00fcresi :<\/strong><\/td>\n8 Hafta (+\/- 2 Hafta)<\/td>\n<\/tr>\n
Prenatal\/ Postnatal:<\/strong><\/strong><\/td>\nPostnatal<\/td>\n<\/tr>\n
Gerekli Numune<\/strong>:<\/td>\nEDTA’l\u0131 Kan (2-4 ml)<\/td>\n<\/tr>\n
Saklama \/ Ta\u015f\u0131ma S\u0131cakl\u0131\u011f\u0131:<\/strong><\/td>\n+ 4C\u00b0\/ + 24C\u00b0<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

T\u00fcm genetik testlerimiz “Hasta Onam Formu”<\/strong> ve “KVKK Formu”<\/strong>nun imzalanmas\u0131n\u0131n ard\u0131ndan \u00e7al\u0131\u015f\u0131lmaya ba\u015flan\u0131r.<\/p>\n

\n

Detayl\u0131 Bilgi Almak \u0130\u00e7in Bize Mesaj Atabilirsiniz.<\/strong><\/p>\n\n\n\n
[contact-form-7 id=”710″ title=”genetik ba\u015fvuru”]<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n

Genoks Genetik Hastal\u0131klar De\u011ferlendirme Merkezi T.C. Sa\u011fl\u0131k Bankanl\u0131\u011f\u0131nca denetlenen ve GHDM-SM\/06.15\/01 ruhsat numaras\u0131 ile hizmet veren sa\u011fl\u0131k kurulu\u015fudur. genoks.com.tr web sayfas\u0131nda bulunan bilgiler, genetik de\u011ferlendirme ve\/veya tan\u0131-te\u015fhis ama\u00e7l\u0131 kullan\u0131lmamal\u0131d\u0131r. T\u00fcm i\u00e7erikler bilgilendirme ama\u00e7l\u0131d\u0131r.<\/p>\n","protected":false},"excerpt":{"rendered":"

BRCA Geni n\u0259dir? GenoXhere BRCA n\u0259l\u0259ri \u0259hat\u0259 edir? BRCA1 v\u0259 BRCA2 homolog rekombinasiya yolu il\u0259 DNT c\u00fct-z\u0259ncir qopu\u011funun t\u0259miri \u00fc\u00e7\u00fcn vacib \u015fi\u015f supressor genl\u0259rdir. H\u0259r hans\u0131 birind\u0259 patojenik germ-line variantlar h\u0259yat boyu d\u00f6\u015f (~55-72% BRCA1, ~45-69% BRCA2), yumurtal\u0131q (~39-44% BRCA1, [\u2026]<\/span><\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"closed","template":"","meta":{"footnotes":""},"doc_category":[205],"doc_tag":[92,105,106],"class_list":["post-3287","docs","type-docs","status-publish","hentry","doc_category-genoks-gdhm-genetik-testler-az","doc_tag-brca","doc_tag-kalitsal","doc_tag-kanser"],"aioseo_notices":[],"year_month":"2026-05","word_count":461,"total_views":0,"reactions":{"happy":0,"normal":0,"sad":0},"author_info":{"name":"admin","author_nicename":"admin","author_url":"https:\/\/genoks.com.tr\/az\/author\/admin\/"},"doc_category_info":[{"term_name":"Genoks GDHM Genetik Testl\u0259r","term_url":"https:\/\/genoks.com.tr\/az\/docs-category\/genoks-gdhm-genetik-testler-az\/"}],"doc_tag_info":[{"term_name":"BRCA","term_url":"https:\/\/genoks.com.tr\/docs-tag\/brca\/"},{"term_name":"Kal\u0131tsal","term_url":"https:\/\/genoks.com.tr\/docs-tag\/kalitsal\/"},{"term_name":"kanser","term_url":"https:\/\/genoks.com.tr\/docs-tag\/kanser\/"}],"aioseo_head":"\n\t\t\n\t\n\t\n\t\n\t\n\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t\n\t\t